Format
Items per page
Sort by

Send to:

Choose Destination

Results: 14

Cited In for PubMed (Select 18395972)

1.

Clinicopathological significance of KAI1 expression and epithelial-mesenchymal transition in non-small cell lung cancer.

Zhou L, Yu L, Wu S, Feng Z, Song W, Gong X.

World J Surg Oncol. 2015 Aug 1;13(1):234. doi: 10.1186/s12957-015-0657-8.

2.

miR-203 Inhibits Frizzled-2 Expression via CD82/KAI1 Expression in Human Lung Carcinoma Cells.

Mine M, Yamaguchi K, Sugiura T, Chigita S, Yoshihama N, Yoshihama R, Hiyake N, Kobayashi Y, Mori Y.

PLoS One. 2015 Jul 1;10(7):e0131350. doi: 10.1371/journal.pone.0131350. eCollection 2015.

3.

A Novel Function of CD82/KAI1 in Sialyl Lewis Antigen-Mediated Adhesion of Cancer Cells: Evidence for an Anti-Metastasis Effect by Down-Regulation of Sialyl Lewis Antigens.

Yoshihama N, Yamaguchi K, Chigita S, Mine M, Abe M, Ishii K, Kobayashi Y, Akimoto N, Mori Y, Sugiura T.

PLoS One. 2015 Apr 29;10(4):e0124743. doi: 10.1371/journal.pone.0124743. eCollection 2015.

4.

Clinicopathological significance of CD133 and CD44 expression in infiltrating ductal carcinoma and their relationship to angiogenesis.

Han Z, Chen Z, Zheng R, Cheng Z, Gong X, Wang D.

World J Surg Oncol. 2015 Feb 15;13:56. doi: 10.1186/s12957-015-0486-9.

5.

The host microenvironment influences prostate cancer invasion, systemic spread, bone colonization, and osteoblastic metastasis.

Ganguly SS, Li X, Miranti CK.

Front Oncol. 2014 Dec 15;4:364. doi: 10.3389/fonc.2014.00364. eCollection 2014. Review.

6.

Knockdown of the T-box transcription factor Brachyury increases sensitivity of adenoid cystic carcinoma cells to chemotherapy and radiation in vitro: implications for a new therapeutic principle.

Kobayashi Y, Sugiura T, Imajyo I, Shimoda M, Ishii K, Akimoto N, Yoshihama N, Mori Y.

Int J Oncol. 2014 Apr;44(4):1107-17. doi: 10.3892/ijo.2014.2292. Epub 2014 Feb 6.

7.

Identification of the tetraspanin CD82 as a new barrier to xenotransplantation.

Saleh SM, Parhar RS, Al-Hejailan RS, Bakheet RH, Khaleel HS, Khalak HG, Halees AS, Zaidi MZ, Meyer BF, Yung GP, Seebach JD, Conca W, Khabar KS, Collison KS, Al-Mohanna FA.

J Immunol. 2013 Sep 1;191(5):2796-805. doi: 10.4049/jimmunol.1300601. Epub 2013 Jul 19.

8.

Tetraspanins as regulators of the tumour microenvironment: implications for metastasis and therapeutic strategies.

Detchokul S, Williams ED, Parker MW, Frauman AG.

Br J Pharmacol. 2014 Dec;171(24):5462-90. doi: 10.1111/bph.12260. Review.

PMID:
23731188
9.

Tetraspanin18 is a FoxD3-responsive antagonist of cranial neural crest epithelial-to-mesenchymal transition that maintains cadherin-6B protein.

Fairchild CL, Gammill LS.

J Cell Sci. 2013 Mar 15;126(Pt 6):1464-76. doi: 10.1242/jcs.120915. Epub 2013 Feb 15.

10.

Tetraspanin CD82 inhibits protrusion and retraction in cell movement by attenuating the plasma membrane-dependent actin organization.

Liu WM, Zhang F, Moshiach S, Zhou B, Huang C, Srinivasan K, Khurana S, Zheng Y, Lahti JM, Zhang XA.

PLoS One. 2012;7(12):e51797. doi: 10.1371/journal.pone.0051797. Epub 2012 Dec 14.

11.

CD82 inhibits canonical Wnt signalling by controlling the cellular distribution of β-catenin in carcinoma cells.

Chigita S, Sugiura T, Abe M, Kobayashi Y, Shimoda M, Onoda M, Shirasuna K.

Int J Oncol. 2012 Dec;41(6):2021-8. doi: 10.3892/ijo.2012.1671. Epub 2012 Oct 17.

12.

Dissecting the diverse functions of the metastasis suppressor CD82/KAI1.

Tsai YC, Weissman AM.

FEBS Lett. 2011 Oct 20;585(20):3166-73. doi: 10.1016/j.febslet.2011.08.031. Epub 2011 Aug 27. Review.

13.

Laminin-binding integrins and their tetraspanin partners as potential antimetastatic targets.

Stipp CS.

Expert Rev Mol Med. 2010 Jan 18;12:e3. doi: 10.1017/S1462399409001355. Review.

14.

Insights into endometrial serous carcinogenesis and progression.

Fadare O, Zheng W.

Int J Clin Exp Pathol. 2009;2(5):411-32. Epub 2009 Jan 10.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk